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CYP/UGT proﬁlesResearch efforts on the human immunodeﬁciency virus (HIV) integrase have resulted in two approved
drugs. However, co-infection of HIV withMycobacterium tuberculosis and other microbial and viral agents
has introduced added complications to this pandemic, requiring favorable drug-drug interaction proﬁles
for antiviral therapeutics targeting HIV. Cytochrome P450 (CYP) and uridine 50-diphospho-glucuronosyl-
transferase (UGT) are pivotal determining factors in the occurrence of adverse drug–drug interactions.
For this reason, it is important that anti-HIV agents, such as integrase inhibitors, possess favorable pro-
ﬁles with respect to CYP and UGT. We have discovered a novel HIV integrase inhibitor (compound 1) that
exhibits low nM antiviral activity against a diverse set of HIV-1 isolates, and against HIV-2 and the simian
immunodeﬁciency virus (SIV). Compound 1 displays low in vitro cytotoxicity and its resistance and
related drug susceptibility proﬁles are favorable. Data from in vitro studies revealed that compound 1
was not a substrate for UGT isoforms and that it was not an inhibitor or activator of key CYP isozymes.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Although the global therapeutic response to HIV/AIDS has seen
tangible progress, this viral pandemic nevertheless continues to ra-
vage both the US and worldwide communities (Trono et al., 2010).
Moreover, co-infection of HIV with tuberculosis (TB) and other
microbial and viral agents has taken the pandemic to an elevated
level of seriousness (Dye and Williams, 2010; Russell et al.,
2010), which has created a critical need for favorable drug–drug
interactions for therapeutics targeting HIV and associated co-infec-
tions (Josephson, 2010; Kiang et al., 2005). Thus, it is vital that anti-
HIV agents, such as integrase inhibitors, exhibit favorable proﬁles
with respect to human phase I and phase II isozymes, particularly
those involving cytochrome P450 (CYP) and uridine 50-diphospho-
glucuronosyltransferase (UGT) (de Montellano, 2005; Tukey and
Strassburg, 2000; Wienkers and Heath, 2005; Williams et al.,2004). These isozymes are pivotal determining factors in the occur-
rence of adverse drug–drug interactions.
HIV-1 integrase (Mr. 32,000) is encoded at the 30-end of the pol
gene and is essential for the replication of HIV (Krishnan and Engl-
eman, 2012). Integration of HIV DNA into the host cell genome re-
quires metal ion cofactors and occurs through several steps
including, site-speciﬁc endonuclease activity of the integrase-
bound viral cDNA (30-processing step), transport of the processed
intasome complex through the nuclear envelope into the nucleus,
integrase-catalyzed transfer of the processed viral cDNA ends into
host chromosomal DNA (strand transfer step) and repair of the
DNA at the integration sites (Frankel and Young, 1998; Hare
et al., 2010; Haren et al., 1999). Research efforts on this crucial
therapeutic target have resulted in two FDA-approved drugs, ralte-
gravir and elvitegravir, for the treatment of HIV/AIDS (Shimura
et al., 2008; Summa et al., 2008). Raltegravir is cleared primarily
through glucuronidation involving the isozyme, UGT1A1, and to a
lesser extent by UGT1A9 and UGT1A3 (Kassahun et al., 2007). Elvi-
tegravir is a substrate for CYP3A4 and this compound and its met-
abolic products are also substrates for UGT1A1 and UGT1A3
(Mathias et al., 2009). The principal route for the metabolism of
integrase inhibitor, S/GSK1349572 (Kobayashi et al., 2011), is also
through UGT (Min et al., 2010).
To explore whether an authentic HIV-1 integrase inhibitor (Nair
and Chi, 2007; Nair et al., 2006; Pommier et al., 2005; Taktakishvili
Fig. 1. Integrase inhibitor 1 (left) and its single crystal X-ray structure (right) depicting the preferred tautomeric form and the conformation in the solid state.
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icant anti-HIV activity but also possess a favorable proﬁle with re-
spect to human CYP and UGT isozymes, we carried out structure–
activity studies based on our earlier compounds with potent HIV-1
integrase inhibitory activities (Seo et al., 2011). These studies led to
compound 1 (Fig. 1) bearing a new integrase recognition motif. The
compound, 4-(5-(2,6-diﬂuorobenzyl)-1-(2-ﬂuorobenzyl)-2-oxo-
1,2-dihydropyridin-3-yl)-4-hydroxy-2-oxo-N-(2-oxopyrrolidin-1-
yl)but-3-enamide, exhibited signiﬁcant antiviral activity against a
diverse set of HIV isolates and an excellent proﬁle with respect
to human cytochrome P450 and uridine 50-diphospho-glucurono-
syltransferase isozymes.2. Materials and methods
2.1. Chemistry
2.1.1. General methods
NMR spectra were recorded on a Varian Inova 500 MHz spec-
trometer. HRMS data were obtained using Q-TOF Ion Mobility mass
spectrometer. UV spectra were recorded on a Varian Cary Model 3
spectrophotometer. 5-Bromo-2-methoxy-pyridine, synthetic re-
agents and solvents were purchased from Aldrich, St. Louis, MO.2.1.2. Synthesis
A concise methodology for the synthesis of compound 1 was
developed that involved 8 steps and an overall yield of 25%. The
key ﬁnal step is described here. To a solution of 4-(5-(2,6-diﬂuo-
robenzyl)-1-(2-ﬂuorobenzyl)-2-oxo-1,2-dihydro-pyridin-3-yl)-2-
hydroxy-4-oxobut-2-enoic acid (1.2 g, 2.71 mmol), prepared using
modiﬁcations of methodologies previously described by us (Seo
et al., 2011), in dimethylformamide (15 mL) was added 1-hydroxy-
benzotriazole (0.55 g, 4.07 mmol), followed by 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (0.57 g,
2.98 mmol) at 0 C. The resulting mixture was stirred at 0 C for
20 min and then 1-(amino)-2-pyrollidinone p-toluene sulfonate,
(0.89 g, 3.25 mmol) and sodium bicarbonate (0.25 g, 2.98 mmol)
were added. Stirring was continued for 2 h at 0–5 C. After comple-
tion of the reaction, the reaction mixture was quenched with water
(50 mL). The resulting yellow solid was ﬁltered and puriﬁed by trit-
uration sequentially with methanol followed by chloroform: pen-
tane (1:1 v/v) to afford compound 1 (1.11 g, 78% yield), m.p.
175–176 C. UV (methanol) k 401 nm (e 9,139), 318 nm (e 6,225).
1H-NMR (CDCl3, 500 MHz): d 15.2 (s,1H), 8.88 (s, 1H), 8.24 (s,
1H), 8.01 (s, 1H), 7.65 (s, 1H), 7.55 (t, 1H), 7.33–7.10 (m, 4H),
6.94 (t, 2H), 5.21 (s, 2H), 3.83 (s, 2H), 3.71 (t, 2H), 2.50 (t, 2H),
2.19 (m, 2H); 13C-NMR (CDCl3, 125 MHz): d 181.2, 179.3, 173.4,
162.2, 162.1, 162.1, 160.2, 160.2, 160.1, 159.5, 159.0, 144.0,
141.7, 132.1, 132.0, 130.4, 130.4, 128.9, 128.8, 124.7, 124.8,
122.5, 122.4, 122.3, 116.6, 115.6, 115.4, 115.0, 111.7, 111.6,111.5, 111.4, 98.5, 47.8, 47.4, 28.4, 24.3, 16.8. HRMS: calcd for C27-
H23F3N3O5 [M + H]+ 526.1590, found 526.1589.
2.1.3. Compound purity
Compound purity was 99.6% (from HPLC data, which was sup-
ported by high-ﬁeld 1H and 13C NMR spectral data and quantitative
UV data).
2.1.4. Molecular modeling and ligand docking on intasome
Molecular modeling of the crystal structure of prototype foamy
virus (PFV) integrase intasome (PDB code 3OYA) with compound 1
docked within the catalytic site was achieved by using the Surﬂex-
Dock package within Sybyl-X [Sybyl-X 1.3 (winnt_os5x) version]
(Tripos, St. Louis, MO, 2011). Processing was done according to de-
fault conditions of Surﬂex-Dock and biopolymer. The prepared li-
gand of compound 1 was docked to the intasome active site as
guided by an appropriately generated protomol. The modeling
was validated by screening a ligand set for compound 1 and a num-
ber of known anti-HIV integrase inhibitors and it was able to rec-
ognize all of the active compounds, including compound 1, as
those with signiﬁcantly high total scores.
2.2. Biology
2.2.1. Materials
All HIV-1 isolates (Gao et al., 1994, 1998; Jagodzinski et al.,
2000; Michael et al., 1999; Vahey et al., 1999; Abimiku et al.,
1994; Owen et al., 1998; Daniel et al., 1985), MT-4 cells, pNL4-3
plasmid DNA (Adachi et al., 1986), HeLa-CD4-LTR-bgal cells (Kimp-
ton and Emerman, 1992), molecular clones for HIV-1 integrase
mutations (Reuman et al., 2010), and Sup-T1 cells (Smith et al.,
1984) were obtained from the NIH AIDS Research and Reference
Reagent Program. Integrase-pBluescript was obtained from the
HIV Drug Resistance Program, NCI, NIH. Other materials were pur-
chased as follows: GeneTailor Site-Directed Mutagenesis System
and High Fidelity Platinum Taq DNA Polymerase (Invitrogen, Carls-
bad, CA); PCR primers (Operon Biotechnologies, Germantown,
MD), pBluescript SK(+) cloning vector and XL10-Gold Ultracompe-
tent cells (Stratagene, La Jolla, CA); Plasmid Miniprep and Gel
Extraction Kits (Qiagen, Valencia, CA); restriction enzymes AgeI
and SalI (New England Biolabs, Ipswich, MA); Rapid DNA Ligation
Kits (Roche Applied Science, Indianapolis, IN).
2.2.2. Antiviral assays in fresh human PBMCs
Fresh human peripheral blood mononuclear cells (PBMCs) were
isolated and used in antiviral assays as previously described (Kor-
tagere et al., 2012; Ptak et al., 2008). Inhibition of HIV-1 replication
was measured based on the reduction of HIV-1 reverse transcrip-
tase (RT) activity in the culture supernatants using a microtiter
plate-based RT reaction (Buckheit and Swanstrom, 1991; Ptak
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based dye, MTS (CellTiter96, Promega).2.2.3. Antiviral assays in MT-4 cells
Compound 1 was solubilized in DMSO to yield 80 mM stock
solutions, which were stored at 20 C until the day of drug sus-
ceptibility assay setup and used to generate fresh working drug
dilutions. The integrase inhibitors, raltegravir and elvitegravir,
were included to study cross-resistance. AZT was a positive control
compound. CPE inhibition assays were performed as described pre-
viously (Adachi et al., 1986). The wild-type parental virus used for
this study was the HIV-1 molecular clone HIV-1 NL4-3. Stocks of
the virus were prepared by transfection of pNL4-3 plasmid DNA
into HeLa-CD4-LTR-bgal cells. Molecular clones for HIV-1 integrase
mutations were prepared by transfection into 293T cells (see be-
low) followed by expansion in Sup-T1 cells. Integrase mutations
for these viruses were conﬁrmed by sequencing following stock
production. These virus stocks, as well as the site-directed mutant
virus stocks produced in 293T cells (see below), were titrated in
the MT-4 cells by serially diluting the virus stocks in tissue culture
media and using the serial dilutions to infect MT-4 cultures. Sam-
ples were evaluated for antiviral efﬁcacy in triplicate for EC50 and
in duplicate for CC50 values.2.2.4. Selection of drug resistant virus isolates
A standard dose escalation method (Buckheit and Swanstrom,
1991; Ptak et al., 2010) employing MT-4 cells infected with HIV-
1 NL4-3 as the parental ‘‘wild-type’’ virus was used to select HIV-
1 isolates that were resistant to compound 1. The virus was serially
passaged, using the virus from the day of peak virus expression to
generate a new acute infection of MT-4 cells and increasing the
concentration of test compound with each passage until drug resis-
tance was identiﬁed or compound cytotoxicity became a limiting
factor. Elvitegravir was included in the passaging in order to pro-
vide comparative data. A no-drug control (NDC) culture was pas-
saged in parallel with the drug-treated cultures. In order to
monitor genotypic changes, the integrase coding region of the
HIV-1 pol gene was sequenced for the viruses from each passage.
Acute infections were initiated by infecting 5  105 MT-4 cells
with a 1:10 dilution of HIV-1 NL4-3 stock virus or peak virus. Cells
and virus were incubated at 37 C for 2–4 h in a single well of a 96-Fig. 2. (A) Representation of compound 1 (black) docked within the active site of modele
a cleft in the modeled HIV-1 intasome electrostatic potential map. The red-brown color
color symbolizes strong local electrostatic potential (most negative). (B) Docking pictu
integrase intasome illustrating the interaction of compound 1 with the amino acid residu
ring (green) with cytosine of DC 16 can be easily discerned. The deoxyribose rings are swell microtiter plate using a total volume of 200 lL. The cells and
virus were then transferred to a T25 ﬂask and the volume in-
creased to 4 mL using media containing an appropriate concentra-
tion of compound 1, or elvitegravir. On day 2–3 post-infection, the
volume was increased to 10 mL, maintaining the concentration of
each test drug. On days post-infection where the supernatant RT
activity was observed to increase to greater than 1000 cpm, cells
were collected by centrifugation, followed by re-suspension in
10 mL of fresh media containing each drug at the appropriate con-
centration. Supernatants removed from the pelleted cells on each
of these days were collected and stored at 80 C. Virus collected
on the peak day of virus production based on RT activity was used
to initiate the next passage.2.2.5. Sequencing of HIV-1 integrase coding region
Virion-associated RNA was extracted from the supernatant
virus pools collected on the peak days of virus replication for each
virus passage. The viral RNA was used as template RNA to amplify
the entire HIV-1 integrase coding region. The DNA sequence of
both strands of the PCR ampliﬁed region was determined by
dsDNA sequencing (University of Alabama at Birmingham Center
for AIDS Research Sequencing Facility). Comparison with the
integrase coding region from wild-type HIV-1 NL4-3 NDC-culture
was also performed.2.2.6. Mutagenesis methodology
Site-directed mutagenesis of the integrase gene from HIV-1
NL4-3 was performed on a portion of pNL4-3, spanning from the
AgeI to SalI restriction enzyme sites, that was sub-cloned into
the pBluescript SK(+) cloning vector (‘‘Integrase-pBluescript’’)
which was used to produce integrase site-directed mutants. Meth-
ylation and PCR ampliﬁcation of the Integrase-pBluescript sub-
clone using the mutagenesis primer sets were performed using
the GeneTailor Site-Directed Mutagenesis System and Platinium
Taq DNA Polymerase. The resulting plasmid PCR ampliﬁcations
were veriﬁed on a 1% agarose gel and then transformed into
DH5a – T1 Escherichia coli cells. Transformed cells were spread
on standard LB-agar plates containing ampicillin and incubated
overnight (37 C) to allow for colony formation. Individual colonies
were isolated, used to inoculate 5–10 mL of standard LB Broth con-
taining ampicillin, and incubated overnight (37 C). Plasmids wered HIV-1 integrase intasome complex (PDB code 3OYA). The inhibitor is shown inside
represents weak local electrostatic potential (most positive) while the blue-purple
re of compound 1 (stick model in green) within the active site of modeled HIV-1
es of integrase (indicated in purple). Stacking interaction of the mono-ﬂuorophenyl
haded in yellow.
Fig. 3. In vitro human liver microsome stability of compound 1. Each bar represents
the average of three determinations with error bars showing standard deviations
from the mean. The positive control compound for these studies was midazolam
(Km for 10-hydroxylation was 2.52 lM). The percent of midazolam (10 lM)
remaining after 1 h under similar conditions was 61.5%.
Table 1
Anti-HIV activity of compound 1 against HIV-1, HIV-2 and SIV isolates in PBMC.
Isolates Type,
subtype
EC50 (±SD)a
nM
Therapeutic
indexb
HIV-1 (Group M)
92RW016 A 20.8 (3.3) 4,625
91US004 B 6.89 (13.4) 13,962
98IN022 C 29.8 (31.8) 3,228
93UG067 D 48.5 (23.5) 1,984
CMU08 E 52.4 (1.6) 1,836
93BR029 F 18.3 (16.1) 5,257
G3 G 34.9 (25.0) 2,756
CDC310342 CRF02-
AG
33.4(31.9) 2,880
HIV-2
CDC310319 HIV-2 86.0 (75.7) 1,119
SIV
MAC251 SIV 19.1(22.4) 5,037
All of the above isolates (HIV-1,
HIV-2 and SIV)
35.0 (31.4)
For HIV-1 Group M subtypes A, B,
C, F
18.9 (9.1)
a EC50 = concentration for inhibition of virus replication by 50%. Data are the
mean of three determinations. SD = standard deviation from the mean of three
independent determinations.
b CC50/EC50 = Therapeutic index.
368 M.O. Okello et al. / Antiviral Research 98 (2013) 365–372extracted from cultures and sequenced to conﬁrm the integrase
coding region and presence of appropriate mutation. Mutated
integrase genes were sub-cloned back into the pNL4-3 backbone.
The ﬁnal mutated NL4-3 plasmids were conﬁrmed to be correctly
constructed by restriction digest and sequence analysis. The mu-
tated pNL4-3 clones were ﬁrst quantiﬁed to determine DNA con-
centration, ethanol precipitated for sterility, and re-suspended in
sterile water. Following transfection, the cells were incubated for
an additional 48 h at 37 C/5% CO2 and then the supernatant was
collected and 1 mL aliquots were frozen at 80 C as stock virus.
Each stock was subsequently analyzed for RT activity and then ti-
trated in MT-4 cells. Sequence analysis of the virus stocks produced
from transfection of the plasmids into 293T cells was performed to
conﬁrm that the resulting viruses maintained the point mutations
associated with the site-directed mutagenesis.
2.3. Human cytochrome P450 and uridine 50-diphospho-
glucuronosyltransferase isozyme studies
2.3.1. Materials
Sources: human liver microsomes (mixed gender, 200 pooled,
Xenotech LLC, Lenexa, KS) and human liver microsomes (mixed
gender, 150 pooled) BD Biosciences, San Jose, CA; NADPH tetraso-
dium salt, UDPGA trisodium salt, G-6-P, G-6-P DH), alamethicin, D-
saccharic acid 1,4-lactone, amodiaquine, dextromethorphan, tes-
tosterone, tolbutamide, triazolam, midazolam, omeprazole, 4-MU,
4-MU b-D-glucuronide and triﬂuoperazine (Sigma, St. Louis, MO);
raltegravir potassium salt, elvitegravir (Selleck, LLC, Houston, TX).
HPLC analyses were performed on a Beckman Coulter Gold 127
system using C18 columns.
2.3.2. Metabolism studies
Incubation mixture (ﬁnal volume of 400 lL) contained human
liver microsomes (protein, 0.5 mg/mL), compound 1 (50 lM in
DMSO (<1% of ﬁnal mixture), G-6-P-DH (0.5 U/mL), and G-6-P
(5 mM) in potassium phosphate buffer (100 mM, pH 7.4) contain-
ing MgCl2 (5 mM). The reaction mixture was pre-incubated for
3 min at 37 C before addition of NADPH (ﬁnal, 2 mM) and then
incubated further at 37 C. An aliquot (60 lL) of the incubation
mixture was taken for each sampling and was quenched with ace-
tonitrile (60 lL). Proteins were removed by centrifugation at
5000g. The supernatant was analyzed on a Beckman Coulter Gold127 system using C18 analytical columns (UV 360 nm, retention
times: compound 1 9.7 min, minor cleavage product (<5%)
13.2 min. The data were analyzed and the results are summarized
in Fig. 3.
2.3.3. Cytochrome P-450 isozyme inhibition assays
Incubation mixtures contained potassium phosphate buffer
(100 mM, pH 7.4), MgCl2 (5 mM), requisite substrate dissolved in
an appropriate solvent, compound 1 (in DMSO) and human liver
microsomes. The reaction mixture (ﬁnal volume 100 lL) was pre-
incubated for 3 min at 37 C prior to the addition of NADPH (ﬁnal,
2 mM). Organic solvent was kept below 1.5%. Each reaction was
terminated by acetonitrile (100 lL), centrifuged and the superna-
tant analyzed by HPLC-UV. A summary of the data and ﬁndings
are presented (see Table 3).
2.3.4. UGT substrate activity in human liver microsomes or cDNA-
expressed isozymes
Incubation mixtures (ﬁnal volume of 500 lL) contained human
liver microsomes (1.0 mg/mL proteins), compound 1 or raltegravir
(50 lM in DMSO, <1% of ﬁnal mixture), UDPGA (4 mM), alamethi-
cin (0.024 mg/mg protein), D-saccharic acid 1,4-lactone (10 mM) in
potassium phosphate buffer (100 mM, pH 7.4) containing MgCl2
(5 mM). Initially, the mixture of human liver microsomes and ala-
methicin in the buffer containing MgCl2 was kept in ice (0 C) for
15 min. D-saccharic acid-1,4-lactone and the test compound were
then added. This mixture was preincubated at 37 C for 3 min
and UDPGA (4 mM) was then added to initiate the reaction. An ali-
quot (60 lL) was removed each sampling time, quenched with ace-
tonitrile (60 lL), centrifuged and the supernatant analyzed by
HPLC and HRMS (see Table 4).
2.3.5. UGT inhibition studies (UGT 1A1, 1A6, 1A9, 2B7)
Incubation mixture (total volume 200 lL) used human liver
microsomes (0.2 mg/mL microsomal proteins), alamethicin
(0.024 mg/mg protein), in potassium phosphate buffer (100 mM,
pH 7.4) containing MgCl2 (5 mM), which was kept at 0 C for
15 min. A solution of compound 1 in DMSO (0–300 lM) and 4-
methylumbelliferone (4-MU, 200 lM, dissolved in methanol) were
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tions were <1.6%. The above mixture was preincubated at 37 C
for 3 min, UDPGA (ﬁnal, 4 mM) was added and the mixture was
incubated for 15 min. The reaction was terminated with acetoni-
trile (200 lL), centrifuged and the supernatant analyzed by
HPLC-UV.
2.3.6. UGT inhibition studies (UGT1A4)
These studies were done in a similar manner to the above UGT
inhibition study, but with triﬂuoperazine as substrate (Uchaipichat
et al., 2006).
3. Results and discussion
Compound 1 (Fig. 1) was synthesized in eight steps and 25%
overall yield from 5-bromo-2-methoxypyridine. Its structure was
conﬁrmed by single-crystal X-ray, UV, HRMS, 1H/13C NMR data,
including gCOSY, HSQC and HMBC correlations. The purity of the
compound used in these studies was 99.6%.
The in vitro anti-HIV activity of compound 1 in human PBMC
cultures is shown in Table 1. The collective data indicate that this
compound has signiﬁcant activity against a broad and diverse set
of HIV-1 subtypes of major group M, as well as against HIV-2
and SIV (mean EC50 35.0 nM). For key Group M subtypes A, B, C
and F, the mean EC50 was 18.9 nM. Therapeutic indices varied from
1119 to 13,962, with the mean being 4,618. Cytotoxicity data (CC50
96,200 nM ± 18,600) gave strong evidence that the compound pos-
sessed low toxicity in human PBMC cultures. Major group M of
HIV-1 and its subtypes are responsible for most HIV infections
(Keele et al., 2006).Table 2
Fold change in susceptibility in MT-4 cells against resistant viruses with key clinical
mutations in integrase.
WT virus or IN
substitutions of resistant
viruses
EC50 fold change compared to wild-type virus
Compound
1
Raltegravir Elvitegravir AZT
WT HIV-1 NL4-3 1.0 1.0 1.0 1.0
Y143C 1.87 826 46.7 1.18
N155H 8.20 88.8 200 3.29
Q148R 18.8 43.3 96.1 NA
E92Q/N155H 6.13 85.5 134 3.45
T66I 5.20 1.0 5.5 1.0
The EC50 against the Wild-Type HIV-1 NL4-3 were 63.5, 6.54, 0.82 and 1.84 nM for
compound 1, raltegravir, elvitegravir and AZT, respectively.
Table 3
Inhibition data for compound 1 against human cytochrome P450 isozymes.
Isozyme Substrate (Metabolite) Substrate Conc. (lM) Prote
CYP 3A4 Testosterone 100 0.3
(6-Hydroxytestosterone)
CYP 3A4 Triazolam 200 0.4
(4-Hydroxytriazolam)
CYP 2D6 Dextromethorphan 200 2.0
(Dextrophan)
CYP 2C8 Amodiaquine 200 0.4
N-dsethylamodiaquine)
CYP 2C9 Tolbutamide 500 0.5
(4-Hydroxytolbutamide)
CYP2C19 Omeprazole 200 0.5
(5-Hydroxyomeprazole)
a IC50 = concentration for 50% inhibition of the speciﬁed CYP isozyme from kinetic data.
(testosterone) was extrapolated from the 100 lM data in this study.
b Percent inhibition of the isozymes by compound 1. The standard deviation is deriveDocking studies suggest that the mechanism of anti-HIV activ-
ity for compound 1 is through inhibition of HIV integrase (Fig. 2).
This is supported by the fact that compound 1 was discovered in
our laboratory from structure–activity studies of closely related
prototypes of compound 1 and also of their precursors, which
showed IC50 data for integrase strand transfer inhibition at low
nM levels (Seo et al., 2011). Further validation of integrase inhibi-
tion came from the observed mutation in the integrase coding re-
gion of the HIV-1 genome, as well as from the cross-resistance data
(discussed below). In addition, the T66I mutation observed for
compound 1 has also been observed in a resistant virus isolate of
elvitegravir, a well-known integrase inhibitor (Goethals et al.,
2008).
In dose escalation studies employing MT-4 cells infected with
HIV-1 NL4-3, the identiﬁcation of HIV-1 isolates resistant to
compound 1 was investigated. The selection of a single amino
acid mutation from threonine to isoleucine at amino acid 66
(T66I) of integrase, began to emerge following passage #4 with
600 nM of compound 1 and became a complete change following
passage #9 (at 19.2 lM). Continued passaging with 20 lM of 1
(up to passage #15) did not result in the emergence of any addi-
tional mutations in integrase. The T66I mutation is in the cata-
lytic core domain of the integrase coding region. In drug
susceptibility studies in MT-4 cells, the fold change in the EC50
of compound 1 against resistant viruses with clinically-relevant
integrase mutations were compared to raltegravir and elvitegra-
vir. These integrase mutant viruses retained susceptibility to
AZT, which was included as the positive control. The results
are summarized in Table 2.
A major focus of this investigation was determination of the
proﬁle of compound 1 towards key human CYP and UGT isozymes
(Dye and Williams, 2010; Tukey and Strassburg, 2000; Wienkers
and Heath, 2005; Williams et al., 2004; Miners et al., 2004). The
cytochrome P450 (CYP) isozymes used in this study are known
to be involved in the clearance mechanisms of about 90% of known
therapeutic drugs. As illustrated in Fig. 3, compound 1 was rela-
tively stable in pooled human liver microsomes. Two key CYP-
mediated metabolites of compound 1 were formed from monoox-
idation of the phenyl rings and their structures were conﬁrmed by
bioanalytical data, including HRMS. CYP isozyme kinetic data re-
vealed that the IC50 for inhibition for compound 1 of CYP isozymes
(3A4, 2D6, 2C8, 2C9, 2C19) were all >200 lM (Table 3). In addition,
compound 1 was not an activator of these CYP isozymes.
UDP-glucuronosyltransferases (UGTs) are a superfamily of hu-
man phase II metabolizing isozymes, which are involved in the glu-in Conc. (mg/mL) Incubation time(min) IC50, lMa (% Inhibition)b
30 >200
(28.0 ± 4.9)
30 >200
(33.4 ± 4.5)
60 >200
(9.2 ± 1.3)
30 >200
(9.1 ± 1.2)
30 >200
(15.5 ± 2.1)
30 >200
(21.8 ± 3.0)
The IC50s for isozymes listed above were not reached at 200 lM. The IC50 for CYP3A4
d from the mean of three determinations.
Table 4
Summary of results for glucuronidation studies of compound 1 and raltegravir.
Compound Microsome or UGT isoform Glucuronide Reversed-phase HPLC retention time
(min), UV detection (nm)
Substrate for
UGT? Yes or No
1 – – 18.6 min, 350 nm
1 pHLM (Xenotech) Nonea – No
1 pHLM (BD Biosciences) Nonea – No
1 UGT1A1 (BD Biosciences) Nonea – No
1 UGT1A3 (BD Biosciences) Nonea – No
Raltegravir – – 30.3 min, 300 nm
Raltegravir pHLM (Xenotech) Glucuronide 16.4 min, 300 nm Yes
Raltegravir pHLM (BD Biosciences) Glucuronide 16.4 min, 300 nm Yes
Raltegravir UGT1A1 (BD Biosciences) Glucuronide 16.4 min, 300 nm Yes
Estradiol – – 27.9 min, 280 nm
Estradiolb pHLM (BD Biosciences) Glucuronides (two) 9.7 min, 11.2 min, 280 nm Yes
Estradiolb UGT1A1 (BD Biosciences) Glucuronide 9.6 min, 280 nm Yes
Methylumbelliferone – – 21.1 min, 318 nm
Methylumbelliferoneb pHLM (Xenotech) Glucuronide 6.1 min, 318 nm Yes
Triﬂuoperazine – – 19.2, 256 nm
Triﬂuoperazineb pHLM (Xenotech) N-glucuronide 18.0 min, 256 nm Yes
a Theglucuronide of compound 1, if formed, would have been observed at a retention time of approximately 8 min. However, no such peak in the HPLC chromatograms
using 254 nm, 300 nm or 350 nm detection wavelengths was observed.
b Estradiol, 4-methylumbelliferone and triﬂuoperazine were used as positive control substrates.
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signiﬁcant number of drugs, including raltegravir (Kassahun
et al., 2007). Thus, in this investigation, the UGT proﬁle of com-
pound 1 was considered to be of high signiﬁcance, both in terms
of HIV co-infection therapeutics (Dye and Williams, 2010; Russell
et al., 2010), and the issue of utilization of UGT-cleared integrase
inhibitors for HIV/AIDS during fetal development and early infancy,
given the low UGT activity during this phase (Strassburg et al.,
2002).
Glucuronidation studies of compound 1 and, for comparison,
raltegravir, were determined in pooled human liver microsomes
veriﬁed to contain UGT 1A1, 1A4, 1A6, 1A9 and 2B7. Compound
1 was not a substrate for these key UGTs in human liver micro-
somes or for speciﬁc cDNA-expressed UGT isozymes, UGT1A1
and UGT1A3 (Table 4). Furthermore, in the kinetic studies in hu-
man liver microsomes, there was no indication of the activation
of UGT isozymes. In contrast, raltegravir was a substrate for UGT
(Fig. 4), which is consistent with previously reported data (Kassa-
hun et al., 2007). We also examined the possible competitive inhi-
bition of UGTs by compound 1 using 4-methylumbelliferone (4-Fig. 4. UGT-catalyzed glucuronidation of compound 1 and raltegravir. Reduction in
percent of raltegravir is due to glucuronidation, and its glucuronide is easily
identiﬁed (HPLC retention times: raltegravir, 30.6 min; raltegravir glucuronide,
16.7 min; monitored through UV detection at 300 nm). The glucuronide of 1 was
not detected [HPLC retention times: compound 1, 14.1 min; its glucuronide
expected at 8 min (monitored at 350 nm, not seen)]. The control consisted of
phosphate buffer (pH 7.4) containing MgCl2, alamethicin, D-saccharic acid 1,4-
lactone, UDPGA and test compound. Error bars show standard deviations from the
mean of three independent determinations.MU), a substrate for multiple isoforms of UGT. However, no evi-
dence for signiﬁcant competitive inhibition of the key UGT iso-
zymes 1A1, 1A6, 1A9 and 2B7 was found (IC50 > 300 lM). In
addition, compound 1was not an inhibitor of another key UGT iso-
zyme, namely UGT1A4.
In summary, we have discovered a new HIV integrase inhibitor
(1), that exhibits signiﬁcant antiviral activity against a diverse set
of HIV-1 isolates, as well as against HIV-2 and SIV and that displays
low in vitro cytotoxicity. It has a favorable resistance and related
drug susceptibility proﬁle. Compound 1 is not a substrate for key
human UGT isoforms, which is of particular relevance, both in
HIV co-infection therapeutics and in HIV treatments during fetal
development and early infancy. Finally, the CYP isozyme proﬁle
of compound 1 suggests that it is not expected to interfere with
normal human CYP-mediated metabolism.
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Glossary
4-MU: 4-methylumbelliferone
NADPH: Nicotinamide adenine dinucleotide phosphate reduced form
UDPGA: uridine 50-diphospho-glucuronosyltransferase
G-6-P: glucose 6-phosphate
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NMR: nuclear magnetic resonance
gCOSY: gradient correlation spectroscopy
HSQC: heteronuclear single quantum coherence
HMBC: heteronuclear multiple bond correlationHSQC: heteronuclear single quantum coherence
HRMS: high resolution mass spectrometry
HPLC: high performance liquid chromatography
UV: ultraviolet
